Strategies based on the use of gene therapy to mitigate the effects of mutations that cause blindness are undergoing rapid development. Novel gene vectors now achieve widespread gene delivery and reduce the risks associated with these approaches. The incidence of genetic mutations that result in rapid deterioration of the ability to see is larger than